Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Project Grant

University of Alberta

$738,226.00

Assessing DGK Alpha as the Key Target for a Promising Immunomodulatory Compound: Mechanism and Implications in cancer immunotherapy

FY 2024-25

Summary
Immunotherapy is like a superhero treatment for cancer, and it won a big award in 2018. We want to find a special medicine that can make it even better. One big problem with cancer is that it can hide from our body's defenses. Specifically, our body has special cells called "T cells" that can fight cancer, but they can get tired and stop working because of cancer. We can use medicines to wake them up and fight cancer again, but these medicines can be expensive and have side effects. Our team found a potential medicine called "compound A" that can wake up these special cells really well, but it has some problems. It doesn't dissolve very well in our body, and we don't know exactly how it works. So, we made a better version called "compound B," and we want to figure out how it works. If we understand it, we can make it even better and help more people with cancer. Our early results show that this could be a big breakthrough in cancer treatment.
Program
Project Grant
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
523156
Name
Barakat Khaled H
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Pharmacology & Toxicology
Projecttitle
Assessing DGK Alpha as the Key Target for a Promising Immunomodulatory Compound: Mechanism and Implications in cancer immunotherapy
Programtype2
Operating Grants
Orgnameinp2
University of Alberta
Cihramount2
$738,226
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Immunotherapy; Mode Of Action; Target Identification
Abstract
Immunotherapy is like a superhero treatment for cancer, and it won a big award in 2018. We want to find a special medicine that can make it even better. One big problem with cancer is that it can hide from our body's defenses. Specifically, our body has special cells called "T cells" that can fight cancer, but they can get tired and stop working because of cancer. We can use medicines to wake them up and fight cancer again, but these medicines can be expensive and have side effects. Our team found a potential medicine called "compound A" that can wake up these special cells really well, but it has some problems. It doesn't dissolve very well in our body, and we don't know exactly how it works. So, we made a better version called "compound B," and we want to figure out how it works. If we understand it, we can make it even better and help more people with cancer. Our early results show that this could be a big breakthrough in cancer treatment.
Competitiondate
202503
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Barakat, Khaled H
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $738,226~ $0~
University of Alberta - $738,226 Grant (2024-25) | Canada Spends